💬In plain words
What the trial is, and whether it could suit you
This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation. Left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation for preventing cardioembolic events in patients with atrial fibrillation. However, the optimal post-procedural antithrombotic regimen following LAAC remains unclear, with no consensus on evidence-based therapy. Given current trends in cardiology favoring reduced-intensity antithrombotic strategies, this study aims to contribute to the evidence base by evaluating whether LAAC followed by reduced-dose apixaban (2.5 mg BID) for 3 months with subsequent complete withdrawal of antithrombotic therapy is superior to long-term standard-dose DOAC therapy in patients with non-valvular atrial fibrillation.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Age ≥18 years;
* Documented nonvalvular AF (≥30 seconds on ECG within previous 12 months);
* CHA2DS2-VASc score ≥3 for women and ≥2 for men;
* Signed informed consent to participate in the study;
Exclusion Criteria:
* Active indication for anticoagulation OTHER than atrial fibrillation at the time of enrollment and/or the predicted/unpredicted occurrence of such indications during the entire study period (e.g., mechanical valve, acute VTE, recent PE requiring \>3 months anticoagulation);
* Inability to tolerate at least 3 months of apixaban therapy (for LAAC arm);
* Indications for antiplatelet therapy or therapy with P2Y12 inhibitors at the time of inclusion and/or the predicted/unpredicted occurrence of such indications during the entire study period;
* The presence of mechanical prosthetic heart valves, mitral stenosis of severe or moderate degree;
* Active DVT requiring anticoagulation;
* Congenital or acquired haemostasis disorders, rheumatic heart disease or recurrent deep vein thrombosis;
* Left ventricular ejection fraction (LVEF) \< 30%;
* Glomerular filtration rate (GFR) \< 30 ml/min (stage IV or V chronic kidney disease) or dialysis patient;
* Severe liver failure, including cirrhosis and Child-Pugh Class C/D;
* NYHA class IV congestive heart failure;
* The patient had a myocardial infarction - MI with or without ST segment elevation (STEMI, NSTEMI) with or without intervention, within 30 days before LAAC;
* The patient had a stroke (of any cause, ischemic or hemorrhagic) within 30 days before LAAC;
* Intracardiac thrombus before LAAC;
* Major bleeding according to BARC criteria (type 3 and higher) within 30 days before LAAC or before randomization;
* Amyloid cardiomyopathy;
* Platelet count \< 100,000 x 109/l;
* The patient participates in another study, with the exception of observational studies without therapeutic interventions;
* Pregnant or breast-feeding patients, patients planning pregnancy during the study period;
* The LAAC procedure was unsuccessful or interrupted for technical reasons;
* PDL (peridevice leak) ≥ 3 mm;
* Contraindications for one of the treatment regimens prescribed by the study protocol (including allergic reactions);
* Planned cardiac or non-cardiac surgical procedure within 30 days before or 90 days after LAAC. Minor procedures not requiring discontinuation of antithrombotic therapy are permitted (e.g., cardioversion, catheter ablation, cataract surgery);
* The patient has a heart tumor, active infection, signs of physiological tamponade;
* The documented life expectancy of the patient is less than 12 months;
HealthTeky